BRIEF-Revelation Biosciences Selects Avance Clinical As Cro For Phase 2/3 Titan Study
Reuters2026/08/19 13:01Revelation Biosciences Inc REVB.O:
REVELATION BIOSCIENCES SELECTS AVANCE CLINICAL AS CRO FOR PHASE 2/3 TITAN STUDY
REVELATION BIOSCIENCES - PHASE 2/3 TITAN STUDY EXPECTED TO BEGIN LATER THIS YEAR
Source text: ID:nBw53q34La
Further company coverage: REVB.O
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
EXCLUSIVE-Nvidia in talks to invest in Anthropic’s mega IPO, sources say
Renova Energia gets B3 extension to meet Level 2 free-float rule until Dec. 31, 2027
DSS names Robert Arthur Simanjuntak chair of nomination and remuneration committee
Site visit: Cyclic Materials opens commercial-scale rare earth recycling plant in Arizona
